Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Calliditas Therapeutics (CALT – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.

Calliditas Therapeutics (CALT)

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Calliditas Therapeutics today and set a price target of $50.00. The company’s shares closed last Friday at $16.40.

According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.4% and a 25.8% success rate. CFA covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, LAVA Therapeutics, and BioAtla.

Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $31.70, which is a 90.5% upside from current levels. In a report issued on August 17, LifeSci Capital also maintained a Buy rating on the stock with a $44.00 price target.

See the top stocks recommended by analysts >>

Regeneron (REGN)

BMO Capital analyst Evan Seigerman assigned a Buy rating to Regeneron today and set a price target of $985.00. The company’s shares closed last Friday at $812.40, close to its 52-week high of $837.55.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.1% and a 47.2% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Bristol-Myers Squibb.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $869.88 average price target, implying a 9.4% upside from current levels. In a report issued on August 6, Barclays also maintained a Buy rating on the stock with a $900.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CALT:

• Calliditas Therapeutics price target lowered to $18 from $21 at Guggenheim
• Calliditas Therapeutics announces FDA acceptance of Tarpeyo sNDA
• Calliditas Therapeutics’ NefIgArd phase 3 trial results published in The Lancet
• Calliditas Therapeutics reports publication of NefIgArd Study data in The Lancet
• CALT Earnings this Week: How Will it Perform?